The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Targeting Heat Shock Proteins on Cancer Cells: Selection, Characterization, and Cell-Penetrating Properties of a Peptidic GRP78 Ligand
Abstract
Peptidic ligands can be used for specific cell targeting and the delivery of payloads into the target cell. Here we describe the screening of a pool of cyclic peptide phage display libraries using whole-cell panning against human melanoma cell line Me6652/4. This strategy resulted in the selection of the cyclic 13-mer Pep42, CTVALPGGYVRVC, which showed preferential internalization into melanoma cell line Me6652/4 versus the reference cell line Me6652/56. This translocation is a receptor-mediated process that does not require electrostatic interactions nor does it involve transfer to the lysosomal compartment. The cellular receptor for Pep42 was identified as the surface membrane form of glucose-regulated protein 78 (GRP78), a member of the heat shock protein family and a marker on malignant cancer cells. The cellular uptake and intracellular trafficking of Pep42-Quantum Dot conjugates was monitored by confocal laser microscopy, and colocalization within the endoplasmic reticulum was observed. The uptake of Pep42 could be blocked by a monoclonal antibody against the identified receptor. Furthermore, Pep42 was shown to target specifically GRP78-expressing cancer cells. The in vitro cytotoxicity of a Pep42-Taxol conjugate was evaluated by flow cytometry wherein the conjugate was shown to induce apoptosis and was more effective in promoting programmed cell death in Me6652/4 cells. In summary, the data presented suggest that cyclic peptide Pep42 might be a powerful tool in the construction of drug conjugates designed to selectively kill malignant cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fernandez, P. M., Tabbara, S. O., Jacobs, L. K., Manning, F. C. R., Tsangaris, T. N., Schwartz, A. M., Kennedy, K. A., & Patierno, S. R. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006332011207 · Cited by 338
Cited by
Sapsford, K. E., Algar, W. R., Berti, L., Gemmill, K. B., Casey, B. J., Oh, E., Stewart, M. H., & Medintz, I. L. (2013) · Chemical Reviews · doi:10.1021/cr300143v · Cited by 1,423
GRP78 Induction in Cancer: Therapeutic and Prognostic Implications
Lee, A. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0325 · Cited by 856
GRP78: A cell's response to stress
Ibrahim, I. M., Abdelmalek, D. H., & Elfiky, A. A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.04.022 · Cited by 647
Wang, M., Wey, S., Zhang, Y., Ye, R., & Lee, A. S. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2485 · Cited by 609
Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential
Lee, A. S. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3701 · Cited by 587
Biju, V., Itoh, T., Anas, A., Sujith, A., & Ishikawa, M. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2185-7 · Cited by 574
Luo, B., & Lee, A. S. (2013) · Oncogene · doi:10.1038/onc.2012.130 · Cited by 560
Ni, M., Zhang, Y., & Lee, A. S. (2011) · Biochemical Journal · doi:10.1042/bj20101569 · Cited by 530
COVID-19 spike-host cell receptor GRP78 binding site prediction
Ibrahim, I. M., Abdelmalek, D. H., Elshahat, M. E., & Elfiky, A. A. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.02.026 · Cited by 509
Case, J. B., Rothlauf, P. W., Chen, R. E., Liu, Z., Zhao, H., Kim, A. S., Bloyet, L.-M., Zeng, Q., Tahan, S., Droit, L., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.021 · Cited by 410
Targeting ER stress induced apoptosis and inflammation in cancer
Verfaillie, T., Garg, A. D., & Agostinis, P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2010.07.016 · Cited by 396
Design of virus-based nanomaterials for medicine, biotechnology, and energy
Wen, A. M., & Steinmetz, N. F. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00287g · Cited by 379
Rational Approaches to Improving Selectivity in Drug Design
Huggins, D. J., Sherman, W., & Tidor, B. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2010332 · Cited by 367
Zhang, Y., Liu, R., Ni, M., Gill, P., & Lee, A. S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.087445 · Cited by 330
ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities
Zamorano Cuervo, N., & Grandvaux, N. (2020) · eLife · doi:10.7554/elife.61390 · Cited by 313
Targeting the endoplasmic reticulum-stress response as an anticancer strategy
Healy, S. J. M., Gorman, A. M., Mousavi-Shafaei, P., Gupta, S., & Samali, A. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.06.064 · Cited by 309
GRP78: A Multifunctional Receptor on the Cell Surface
Gonzalez–Gronow, M., Selim, M. A., Papalas, J., & Pizzo, S. V. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2568 · Cited by 266
Cathepsin-sensitive nanoscale drug delivery systems for cancer therapy and other diseases
Dheer, D., Nicolas, J., & Shankar, R. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.010 · Cited by 144
Engineered Bacteriophage T7 as a Potent Anticancer Agent in vivo
Hwang, Y. J., & Myung, H. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.491001 · Cited by 31
Metadata
- Authors
- Kim, Y., Lillo, A. M., Steiniger, S. C. J., Liu, Y., Ballatore, C., Anichini, A., Mortarini, R., Kaufmann, G. F., Zhou, B., Felding-Habermann, B., & Janda, K. D.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2006-07-01
- Volume
- 45
- Issue
- 31
- Pages
- 9434-9444
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2082053057
- Cited by
- 187
- References
- 1
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.